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Abstract
Objectives—The diagnosis of cervical lymph node metastasis in head and neck squamous cell
carcinoma (HNSCC) patients constitutes an essential requirement for clinical staging and
treatment selection. However, clinical assessment by physical examination and different imaging
modalities, as well as by histological examination of routine lymph node cryosections can miss
micrometastases, while false positives may lead to unnecessary elective lymph node neck
resections. Here, we explored the feasibility of developing a sensitive assay system for desmoglein
3 (DSG3) as a predictive biomarker for lymph node metastasis in HNSCC.
Materials and Methods—DSG3 expression was determined in multiple general cancer- and
HNSCC-tissue microarrays (TMA), in negative and positive HNSCC metastatic cervical lymph
nodes, and in a variety of HNSCC and control cell lines. A nanostructured immunoarray system
was developed for the ultrasensitive detection of DSG3 in lymph node tissue lysates.
Results—We demonstrate that DSG3 is highly expressed in all HNSCC lesions and their
metastatic cervical lymph nodes, but absent in non-invaded lymph nodes. We show that DSG3 can
be rapidly detected with high sensitivity using a simple microfluidic immunoarray platform, even
in human tissue sections including very few HNSCC invading cells, hence distinguishing between
positive and negative lymph nodes.
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Conclusion—We provide a proof of principle supporting that ultrasensitive nanostructured
assay systems for DSG3 can be exploited to detect micrometastatic HNSCC lesions in lymph
nodes, which can improve the diagnosis and guide in the selection of appropriate therapeutic
intervention modalities for HNSCC patients.
Keywords
DSG3; Head and Neck Cancer; Desmosomes; Biomarker; Sentinel Lymph Nodes; Nanosensors
Introduction
With more than 500,000 new cases annually, squamous cell carcinomas of the head and
neck (HNSCC) represent one of the ten most common cancers globally 1, and result in more
than 11,000 deaths each year in the US alone 2. The five year survival of newly diagnosed
HNSCC patients is ~50%, and despite new treatment approaches, it has improved only
marginally over the past decades 3. HNSCC has a high propensity to metastasize to
locoregional lymph nodes due to the presence of a rich lymphatic network and the overall
high number of lymph nodes in the neck region 3–8. Even in patients without clinical
evidence of lymph node involvement (N0), there is a high incidence of occult lymph node
metastasis, ranging from 10 to 50% 4,5,7. The diagnosis of cervical lymph node metastasis
an essential requirement for clinical staging and treatment 9, and is now widely accepted as
the most important factor in HNSCC prognosis 3,5,6,10. However, due to limitations in the
accurate diagnosis of lymph node metastasis, patients with clinically negative nodes often
undergo elective neck resection or radiation 11,12, with the consequent associated morbidity
and adverse impact in the quality of life 12.
Clinical assessments of lymph node metastases include physical examination, imaging
modalities such as computed tomography (CT), magnetic resonance imaging (MRI),
ultrasonography, and [18F]-2-fluorodeoxyglucose positron emission tomography scans
(PET) 13,14. However, poor spatial resolution, false positive detection of reactive lymph
nodes, and limited sensitivity under 5 mm size 15–18, can add to potential false negative
results. Histopathological, immunohistochemical (IHC), and molecular approaches to
evaluate sentinel lymph node biopsies have improved the detection rate of metastatic disease
in some cancers 19,20, but histopathology-based methods can often miss micrometastases,
while more sensitive techniques such as IHC and real-time PCR for validated cancer
markers are time consuming and require stringent handling procedures and technical
expertise.
A recent proteomic analysis of paraffin embedded normal oral mucosa and HNSCC lesions
revealed a very high abundance of Desmoglein 3 (DSG3) in both non-neoplastic epithelium
and cancer lesions 21. DSG3 is a transmembrane glycoprotein involved in cell-to-cell
adhesion that is exclusively expressed in stratified epithelium 22. These observations
prompted us to explore whether the assessment of DSG3 protein levels could be used to
investigate the presence of malignant squamous epithelial cells in cervical lymph nodes, and
hence serve as a predictive biomarker for metastasis. In this regard, high sensitivity
electrochemical immunoassays have recently gained acceptance in biomedicine 23. For
example, we have developed immunosensors based on nanostructured electrodes coupled to
microfluidics and multilabel strategies to achieve highly sensitive detection of protein cancer
biomarkers in serum 24,25. We have combined these strategies into a simple microfluidic
immunoarray 26, 27 and here explore the suitability of this platform for the rapid and
sensitive detection of DSG3 protein. We show that this system can be used to rapidly detect
and quantify DSG3 in frozen human tissue sections, distinguishing between clinically
positive and negative cervical lymph nodes. Overall, these studies may help develop point-
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of-care procedures aiding in the diagnosis of invaded lymph nodes in HNSCC patients,
thereby facilitating educated decisions regarding appropriate therapeutic intervention
modalities, and decreasing the morbidity often associated with HNSCC.
Materials and Methods
Reagents, Antibodies, and Cell Culture
All chemicals and reagents were from Sigma-Aldrich (St Louis, MO), unless indicated. The
following antibodies: goat-anti human DSG3 [AF1720]; mouse-anti human DSG3
[MAP1720], biotin labeled goat-anti human DSG3 [BAF1720], recombinant human DSG3
Fc Chimera protein [1720-DM], were from R&D Systems (MN, USA). The mouse anti-
human DSG3 antibody [32–6300] from Invitrogen (MA, USA), and rabbit-anti-cytokeratin
Wide Spectrum Screening [N1512] from Dako (CA), were used for immunohistochemistry
(IHC). The -tubulin antibody [11H10] was from Cell Signaling Technology (MA, USA).
Biotinylated peroxidase and streptavidin coated magnetic beads were from Invitrogen. Anti
–rabbit and anti-mouse biotinylated secondary antibodies were from Vector, Burlingame,
CA, US. HN12, HN13 and HN30 cells were described previously 28. Cal27 and Jurkat cells
were from ATCC (VA); and primary human cells from Lonza (MD). See Supplemental
Information for additional information.
Human Clinical Tissues and Tissue Microarrays (TMA), Immunohistochemistry and
Immunofluorescence
Formalin fixed, paraffin-embedded, and freshly frozen HNSCC and lymph node samples
were obtained anonymized with Institutional Review Board approval. Five μm sections
from all tissues underwent standard H&E staining for histopathological evaluation and
immunostaining. Tissue microarrays used include TMA MC2081 US (Biomax, MD) with
208 representative cases of colorectal, breast, prostate and lung cancers, and normal tissue;
TMA LC810 (Biomax, MD), consisting of 40 cases of different types of lung cancers with
their matched metastatic lymph nodes (total 80 tissue cores); and the Head and Neck Tissue
Microarray Initiative, including 317 HNSCC cases29. Tissue processing and analysis are
described in detail in Supplemental Information. All slides were scanned at 400x
magnification using an Aperio CS Scanscope (Aperio, CA) and quantified using the
available Aperio algorithms. Immunodetection of DSG3 was quantified according to percent
of tumor cells stained (1–25%, 26–50%, 51–75%, or 76–100%)29. For immunofluorescence,
10μm cryosections were immunostained with goat-anti human DSG3 (AF1720), mouse-anti
vimentin and DAPI containing. See Supplemental Information for additional details.
Western Blot Analysis of Cell and Tissue Extract, and Microfluidic Immunoarrays Systems
for DSG3
A detailed description of the procedures used for tissue lysate preparation, SDS-PAGE gel
analysis and Western blotting, and the fabrication of the microfluidic immunoarrays made of
gold nanoparticles layered with glutathione are described in detail in the Supplemental
Information. Briefly, the immunoarrays consisting of 8 sensor elements, made of gold
nanoparticles layered with glutathione, were first coated with the capture antibody and
transferred to a microfluidic chamber. In parallel, biotinylated horseradish peroxidase and a
biotinylated secondary antibody were attached to streptavidin-coupled magnetic beads and
collected with a magnet. Next, 5 μl of 5–750 fg/mL of recombinant DSG3 protein standards
or 4 μl tissue extract were diluted 1:6000 in RIPA buffer and added to the bioconjugates.
The bioconjugates with captured proteins were then magnetically separated, washed,
resuspended in a final volume of 110 μL, and immediately injected into the microfluidic
channel housing the immunoarrays. At this step, the flow was stopped, incubated for 20 min,
washed, and hydroquinone solution was passed through the channel. The amperometric
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signal was developed by injecting 50 μL of 100 μM H2O2. Tissue lysates used for Western
blot analysis and microfluidic immunoarrays were made from primary tumors (n=4), lymph
node (−) (n=3), and lymph node (+) (n=3).
Results
In a previous proteome-wide analysis of HNSCC progression, we noted that DSG3 was
highly expressed in normal oral mucosa and HNSCC lesions 21. To further investigate a
possible use for DSG3 as a predictive biomarker, we first assessed DSG3 expression by
immunohistochemistry in an independent cohort of human normal and malignant oral
squamous tissues. By H&E histological evaluation, normal squamous epithelium shows a
defined basement membrane with layers of differentiating keratinocytes, whereas in the
malignant counterpart, this organized pattern is lost (Fig 1A). Normal tissues sections
stained for DSG3 show that it is predominantly expressed in the basal and suprabasal layers
of the normal squamous epithelium, while in SCC DSG3 expression is restricted to cancer
cells. Stromal cells were negative. We next evaluated DSG3 expression in a HNSCC tissue
microarray (TMA) containing 317 evaluable cores 29. DSG3 was readily detected in all
HNSCC cores and localized to tumors cells (Fig 1B). Within these cases, well-differentiated
carcinomas (n=120) had the highest percentage of DSG3-positive cells (~90%). The
moderate- (n=119), and poorly-differentiated (n=66) cores showed slightly lower proportion
of DSG-reactive cells (80% and 70%, respectively), the remaining 12 cores consisting of
corresponding to non-squamous tissues were negative for DSG3 (Fig. 1C). The data
demonstrates that DSG3 is highly expressed in human oral squamous epithelium and
HNSCC.
We next sought to assess in vitro the specificity of the epithelial expression of DSG3 in a
panel of squamous and non-squamous model cells. The latter included Jurkat cells
(immortalized T lymphocyte cells), HMVEC (skin human microvascular endothelial cells),
LEC (lymphatic endothelial cells), and HUVEC (human umbilical vein endothelial cells).
HaCaT cells are squamous, non-oral immortalized epidermal keratinocytes, while the oral
squamous cell carcinoma lines included HN12, HN13, HN30 and Cal27 28. DSG3 was
readily detected in all squamous oral cancer cell lines and HaCaT cells, with lower levels in
HN12 and higher in Cal27 (Fig 1D). No expression for DSG3 was observed in any of four
non-squamous lines, while levels of α-tubulin indicated equal loading as well as protein
integrity. The data seem to indicate that DSG3 is exclusively expressed in squamous
epithelial-derived cells.
To further validate the specificity of DSG3 expression, we evaluated TMAs containing cores
representing the four most common cancers (breast, lung, prostate, and colon cancer) for
DSG3 levels, and scored cases based on the presence or absence of DSG3 expression. As
seen in Fig 2A), DSG3 is poorly expressed in breast and prostate cancers, as well in
adenocarcinoma of the lung (ADC), which likely reflects the glandular epithelial cell origin
of these human malignancies. In colon carcinoma, the expression was variable, and in all
cases the pattern of expression was diffused and not the characteristic membrane lace-like
pattern. In contrast, DSG3 is highly expressed in tumors derived from cells of squamous
epithelial origin, such as lung squamous carcinoma (SCC) and additional oral squamous
carcinoma (OSCC) that were included in these arrays, showing a membrane localized
staining. All stainings were scored blindly and tabulated (Fig 2A). All cancers of squamous
origin (oral and lung SCC) were strongly positive for DSG3 expression. As lung cancers
include SCC, ADC, and small cell lung carcinomas (SCLC), we examined further the
specificity of DSG3 expression in these distinct lung cancer lesions. All lung SCC show
strong membrane localized staining in both the primary tumor and metastasis, while ADC
and SCLC show marginal to no DSG3 expression, as reflected by scoring their
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corresponding tissue cores (Fig 2B). Collectively, our results indicate the high specificity of
DSG3 expression in oral and lung SCC lesions.
Based on the observation that DSG3 is highly expressed in HNSCC, we wanted to determine
if the presence of this protein in cervical lymph nodes of the neck region could be used as a
predictive biomarker of HNSCC invasion. To this end, we evaluated formalin-fixed,
paraffin-embedded and anonymized tissue sections of non-metastatic (N0) or metastatic (N
+) human cervical lymph node biopsies from patients diagnosed with HNSCC for
expression of DSG3 and cytokeratin, a squamous-specific protein marker. Negative lymph
nodes were negative (Fig 3A) whereas clusters of tumor cells stained positive for
membrane-localized DSG3 (inset, top right), can be seen throughout the invaded lymph
node (N+), indicating the metastatic spread of squamous tumor cells of the primary tumor
lesions from the oral cavity (Fig 3A). Noteworthy, small clusters of 2–3 isolated tumor cells,
constituting micro-metastases were readily detected by the presence of DSG3 protein, and
this size tumor island could potentially be missed by histopathological evaluation (Inset).
Next, we screened a larger cohort of metastatic and non-metastatic human cervical lymph
nodes for cytokeratin and DSG3 expression (n=35). All metastatic (n=30), but not non-
metastatic cases (n=5) were positive for DSG3. Serial sections stained for H&E and
cytokeratin confirmed the epithelial nature of the malignant DSG3-positive cells. (Fig 3B,
and low magnification of a whole lymph node in Supp Fig 1). This indicates that DSG3
expression can help identify small numbers of malignant squamous tumor cells in lymph
nodes, and hence the metastatic nature of the primary lesion. The sensitivity and specificity
of this detection suggests that DSG3 may hold promise for accurately detecting
micrometastasis in cervical lymph nodes in newly diagnosed HNSCC patients.
Our previous study adapted amperometric sandwich immunoassays to a microfluidic system
for the ultrasensitive, multiplexed detection of secreted biomarker proteins 26. Here, we used
a similar strategy for detecting DSG3 in complex tissue extracts using the microfluidic
immunoassay system. As shown in Fig 4A, DSG3 capture antibodies are attached to up 8
sensor elements, and streptavidin-coated paramagnetic beads (MB) loaded with 400,000
biotin-HRPs and thousands of secondary biotin-labeled antibodies to DSG3 (Ab2) are used
to capture the protein off-line. After washing and magnetic separation, the MBs that have
bound DSG3 (DSG3-MB) are injected into the microfluidic channel. Incubation at stopped
flow allows the sensor antibodies to capture DSG3-MBs, and amperometric signals are
developed by injecting hydrogen peroxide to activate HRP and hydroquinone to mediate the
amperometic oxidation, , resulting in peak currents proportional to DSG3 concentration (Fig
4B). Noteworthy, the entire assay from incubation of sample with Ab2-MB-HRP to
measurement takes ~50 min. Remarkably, using this approach we were able to accurately
and reproducibly detect DSG3 protein at levels down to 5 fg mL−1 in complex tissue
extracts, with minimal non-specific binding.
We next used these protocols for capturing DSG3 from clinical samples of human HNSCC.
Desmosomes are notoriously insoluble, and multiple buffers tested, RIPA buffer afforded
excellent solubility and retaining antigenicity of DSG3 extracted directly from cryosections
of HNSCC and lymph node tissue. Protein extracts were made from a single 10 μm
cryosection from each sample and used as input. Picogram levels of DSG3 protein were
detected in all tumor samples (T1–4), and this was confirmed by Western blot analysis,
where high levels of the protein were also detected in total cell extracts that were used for
these analyses (Fig 4C and 4D).
The specificity of DSG3 identification was further confirmed by simultaneous fluorescence
microscopy of DSG3 and vimentin, as a stromal marker, in frozen sections of a series of
metastatic and non-metastatic lymph nodes. As seen in Fig 5A, only vimentin (red) was
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identified in non-metastatic lymph nodes (in blue, nuclear DAPI staining), whereas all
metastatic lymph nodes showed pockets of very strong staining for DSG3 (green).
To further explore the sensitivity of the method, we decided to analyze metastatic lymph
node tissues in which the number of malignant epithelial cells was known. For this, H&E
stained slides of each case was scanned, analyzed histologically, the malignant areas
identified, and the number of cells quantified using the Aperio nuclear algorithm (Aperio,
Vista, CA). The number of cancer cells per lymph node section is indicated in Table 1. No
tumor cells were be present in the negative lymph nodes, while all three metastatic lymph
nodes (1–3) evaluated had differing number of tumor cells. Noteworthy, positive lymph
node 1 had less than 1,000 tumor cells, while the remaining had between 13,000–16,000
cells (Table 1). Using the nanosensors, we evaluated total protein extracts from lymph nodes
for levels of DSG3. As seen in Fig 5A, DSG3 was essentially not detected in the normal
lymph nodes, with marginal values likely a reflection of very limited residual non-specific
binding of Ab2-MB-HRPcomplex, giving rise to minimal amperometric signal. In contrast,
all of the positive, metastatic lymph nodes showed high levels of DSG3 protein expression.
To validate these measurements, the same protein extracts were also analyzed by Western
blotting (Fig 5B). No DSG3 was detected in the negative lymph nodes, while in all the
positive lymph nodes, bands for DSG3 and its multiple glycosylated forms were readily
seen, and the intensity of the corresponding bands correlated with DSG3 levels quantified by
the nanosensors. When total DSG3 was normalized by the number of tumor cells in each
metastatic lesion, positive lymph nodes expressed approximately 150 fg DSG3 per tumor
cell (Table 1), well above the threshold for DSG3 detection. Together, this indicates that the
nanosensor-based detection of DSG3 could be a highly sensitive and specific method for the
identification of squamous carcinoma metastases in clinical practice. This rapid method was
capable of measuring DSG3 levels even from as little as a single cell, suggesting that this
technique may represent a potent tool for the ultrasensitive detection of the presence or
absence of lymph node invasion in human oral cancer patients.
Discussion
The spread of primary HNSCC lesions to locoregional lymph nodes has often already
occurred at the time of diagnosis, thus compromising the prognosis and long-term survival
of HNSCC patients 3. Accurate diagnosis of lymph node metastases remains difficult, and
many patients that do not present cancer dissemination to the lymph nodes (N0) may be
subjected to unnecessary elective surgery. On the other hand, small lesions may be difficult
to identify within the lymph nodes in cryosections when histophatologic evaluation is
performed while the patient is in the operating room. Hence, some patients may miss a
therapeutic opportunity due to false negative diagnosis of lymph node metastasis. Here, we
demonstrate that DSG3 is expressed in normal oral squamous mucosa, and in all HNSCC
lesions and their metastatic cervical lymph nodes. Indeed, the presence of DSG3 in lymph
nodes can be exploited to detect micrometastatic lesions, which can serve as a sensitive
marker of HNSCC progression. We also show the feasibility of using a rapid, low-cost
nanostructured immunoarray device for the detection of DSG3 protein in metastatic lymph
nodes in newly diagnosed HNSCC patients, which can improve diagnosis and guide the
most effective therapeutic options.
Most current technologies for cancer detection and diagnostics are not suitable for the
differentiation of normal versus metastatic lymph nodes at early stages of cancer
progression, and efforts to address this gap have been met with mixed results. Currently, the
gold standard for identification of metastasis is the serial sectioning and histopathological
analysis of tissue specimens by H&E staining and immunohistochemistry 30. This provides
key information needed for TNM (tumor-node-metastasis criteria) classification of HNSCC
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patients. However, a risk remains that micrometastases may go undetected in otherwise
negative lymph nodes. IHC performed on serial sections for cytokeratin may help in
detecting metastases, but unfortunately this low-throughput method requires significant
investment of time and expense, and it is often performed after surgery. Considering the
false-negative rate and the sampling error that are encountered by H&E examination alone, a
reliable and rapid predictive test to determine lymph node metastases is needed 31.
Application of new technologies such as real-time quantitative PCR (qPCR), to look at
mRNA levels of molecules expressed by oral squamous tissues have shown encouraging
results 32. While this improves upon some of the limitations of IHC detection of
cytokeratins, independent studies have found some inconsistencies in the precise cytokeratin
to be analyzed. For example, from a three-marker analysis, only cytokeratin 14 was reliably
detected by qPCR in several oral cancer cell lines and tissues, and sensitive enough to detect
down to a single cancer cell in a background of Jurkat cells, essentially representing a model
of lymph node metastasis 33. In another study, cytokeratin 17 was demonstrated to be far
superior at discriminating positive lymph nodes while cytokeratin 14 was less informative,
although in parallel histological analysis, this was only achieved if metastasis had exceeded
450 μm, leaving a high probability of micrometastasis going undetected 34. While the
sensitivity of qPCR for detecting cytokeratins is unquestionable, its ability to reliably and
consistently detect these molecules in a single tumor cell embedded within normal
lymphatic tissues still remains a challenge.
The met-receptor is over-expressed in several metastatic carcinomas including
HNSCC 35,36, and with minimal to none in lymphatic cells, its presence in lymph nodes may
be exploited for predicting metastasis. Indeed, qPCR analysis detected met expression in
40% of invaded lymph nodes, and interestingly exceeding the sensitivity of cytokeratins,
which were tested in the same sample cohort 37. Use of multiple markers may improve
detection of metastatic lymph nodes, and in this regard, mRNA for DSG3 (referred to as
pemphigus vulgaris antigen, PVA) and TACSTD1 (tumor-associated calcium signal
transducer 1), have been previously reported to be highly expressed in HNSCC, and
successfully integrated into a multiplex qRT-PCR assay for metastatic prediction, achieving
a remarkable accuracy 38,39. DSG3 mRNA levels in lymph nodes have been also touted as
potential predictors of HNSCC progression 38,40. Generally, the use of qPCR greatly
improves the sensitivity of detection of target genes, but the need of high quality RNA
extracted from tissues remains a significant technical hurdle, such as the presence of
contaminants and RNA degradation that can severely interfere with data interpretation. It is
noteworthy that mRNA levels may not accurately reflect protein expression, as many post
translational regulatory processes may allow or prevent the accumulation of translated
products, and for predictive biomarkers, the presence of the target protein may be better
suited.
In this regard, our proteomics analysis of HNSCC and normal oral epithelial tissues
suggested that DSG3 is preferentially expressed in squamous tissues 21. By examining
hundreds of cancer lesions representing some of the most prevalent human malignancies we
now show that DSG3 is highly expressed in all tumors derived from cells of squamous
epithelial origin, such as lung SCC and HNSCC, with more variable expression in
adenocarcinomas of the colon, prostate, breast and lung, likely reflecting their glandular
epithelial cell of origin. For HNSCC, we noticed a lower expression of DSG3 in poorly
differentiated lesions, aligned with prior reports 41. However, all HNSCC cases analyzed
expressed DSG3, albeit in some lesions not all tumor cells expressed this marker. Thus,
although the possibility exists that in some invaded lymph nodes the level of DSG3 may be
below our detection limit, our collective findings indicate that DSG3 is highly expressed in
all human SCCs but not expressed in normal lymph nodes, and that DSG3 can be detected
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even in small clusters of malignant cells invading the lymph nodes, thus serving as a marker
for the metastatic spread of the cancerous lesions. We now exploited this information, the
availability of highly specific monoclonal antibodies detecting different epitopes in DSG3,
and our recently established biomarker detection platform using microfluidic immunoarray
devices featuring nanostructured electrodes 26, to develop an assay system enabling the
rapid and ultrasensitive detection of DSG3 protein in complex tissue extracts, with minimal
non-specific binding. The method was sensitive enough to detect isolated tumor cells, and
certainly small groups of cells in a single cryosection of a positive lymph node.
Taken together, we can conclude that the ability to quantitate femtogram levels of DSG3 can
be used for the intraoperational detection of the presence of even few invasive human
squamous epithelial cells in cryosections of lymph nodes of HNSCC patients, hence aiding
the pathologists and surgeons to make informed decisions about appropriate treatment
options. We expect that similar approaches can be used to optimize the detection of
additional cancer biomarkers in lymph node sections, thus increasing the basis for successful
clinical prediction. Collectively, combined with a simple work-flow and a short assay time,
these features described in this study, hold promise for the development of point-of-care
clinical screening techniques to identify HNSCC patients with metastatic disease. Indeed,
the encouraging results described in this proof of principle study may provide the rationale
for future validation of this diagnostic strategy in larger multicenter studies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Validation of DSG3 expression in normal and malignant HNSCC
Normal oral mucosa biopsies and HNSCC were evaluated for DSG3 by IHC. A. DSG3 is
expressed throughout the normal epithelium, but is stronger in the basal and parabasal
layers. Diffuse expression was seen in the epithelial component of all HNSCC. B.
Representative well (WD), moderate (MD) and poorly (PD) differentiated HSCC cases are
shown. C. DSG3 was expressed in all tumors regardless of differentiation, with increased
expression in WD cases. Numbers of cases analyzed is depicted. D. Total cell extracts from
non-squamous (Jurkat, HMVEC, LEC, HUVEC) and oral-squamous (HN12, HN13, HN30,
Cal27), and epidermal-squamous (HaCaT) were processed for Western blot analysis. Native
DSG3 and its glycosylated forms were readily detected in squamous cells extracts, while
absent from the non-squamous counterparts. These levels were compared with human
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recombinant DSG3 that was processed in a background of Jurkat cell lysate. Tubulin
staining indicates equivalent loading and protein integrity.
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Figure 2. Immunoreactivity of DSG3 in common tumor types
A. Multi-tumor TMAs (lung, breast, colon, prostate), and an oral specific TMA were
assessed for DSG3 expression by IHC, and the staining scored for the presence of specific
staining as (+) or (-). Most squamous cell lung cancers stained positive for DSG3, but very
few of the adenocarcinomas gave positive reaction. All cores from the OSCC TMA scored
positive. B. In lung cancer, DSG3 expression was positive in most squamous cell
carcinomas (SCC) including lymph node metastasis (SCC Met), while few cases of
adenocarcinomas (ADC) gave positive reaction, and all small cell lung carcinoma samples
(SCLC), were negative.
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Figure 3. Specific detection of DSG3 in human cervical lymph nodes
A. Formalin fixed and paraffin embedded tissue sections of non-metastatic (N−) and
metastatic lymph nodes (N+) show DGS3 expression only in N+, with the staining localized
to the malignant squamous cells (n=30). All N− cases were negative (n=5). B. The epithelial
specificity of DSG3 immunoreactivity was further confirmed using simultaneous cytokeratin
(CK) staining. A representative example is shown, whereby the H&E stained tumor island is
matched with CK and DSG3 expression, with no non-specific staining. An example of a N−
case stained for DSG3 is shown.
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Figure 4. Rapid and ultrasensitive detection of DSG3 in human HNSCC samples using
nanosensors
A. Scheme used for the ultrasensitive detection by the microfluidic immunoarray showing a
single sensor in the array with capture DSG3 antibodies attached. Proteins are captured off-
line on Ab2-magnetic bead (MB)-HRP bioconjugates, and after magnetic separation and
washes, the MBs are injected into the immunoarray containing 8 sensors. A single
immunoarray sensor is depicted. Following incubation, amperometric signals are generated
by applying −0.3 V vs Ag/AgCl to the sensors by injecting a mixture of HRP-activator H2O2
and mediator hydroquinone (HQ). B. Varying recombinant DSG3 protein concentrations
were used to generate a calibration plot. The sensitivity of DSG3 sensor using recombinant
protein was 5646 nA mL [fg protein]−1 cm−2. C. Protein extracts of primary human oral
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squamous carcinomas (T 1–4) made with RIPA buffer were processed for detection of
DSG3. High DSG3 levels were found to be present in all the samples, and this was
confirmed by Western blot analysis of the same extracts for DSG3 (D). Tubulin was used as
loading control.
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Figure 5. Detection of DSG3 in metastatic human cervical lymph nodes
H&E stained cryosections of representative non-metastatic (−) and metastatic (+) human
cervical lymph nodes were scanned and the total number of tumor cells per section was
quantified (Table 1). Serial sections of these lymph nodes were evaluated by
immunofluorescence for DSG3 and detected only in metastatic lymph nodes (green).
Vimentin (red) was used to identify stromal tissue, and nuclei of all cells were stained blue
with DAPI (Fig. 5A). Protein extracts made from single cryosections of lymph nodes were
used for the detection of DSG3 by Western blot analysis and DSG3 quantification using
nanosensors. DSG3 levels were similar to background for all non-metastatic samples, while
DSG3 levels in all metastatic cases were proportional to the number of invading HNSCC
cells (Fig. 5B).
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Table 1
DSG3 detection in metastastic lymph nodes
Cryosections of non-metastatic (N−)(n=3) and metastatic (N+)(n=3) human cervical lymph nodes were
collected and analyzed by nanosensor detection. The total number of tumor cells per cryosection was
evaluated, and used to estimate the total amount of DSG3 per tumor cell.
Samples Detected DSG3 (pg/mL) Tumor cells per section Detected DSG3 (fg/tumor cell)
N−1 0.01 - -
N−2 0.03 - -
N−3 0.02 - -
N+1 427 697 202
N+2 6,274 13,843 150
N+3 4,512 16,576 90
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